In a patient with chronic kidney disease stage 3b (eGFR 41 mL/min/1.73 m²), what does a serum CO₂ (bicarbonate) level of 36 mEq/L indicate and how should it be managed?

Elevated CO2 (Bicarbonate) of 36 mEq/L in CKD Stage 3b

A serum bicarbonate of 36 mEq/L in CKD stage 3b is abnormally elevated and warrants investigation for the underlying cause, as high bicarbonate levels are associated with increased mortality risk in CKD patients.

Understanding the Finding

Your patient's bicarbonate level of 36 mEq/L exceeds the normal range (typically 22-29 mEq/L) and represents metabolic alkalosis rather than the metabolic acidosis commonly seen in CKD. This is clinically significant because:

• High bicarbonate is associated with worse outcomes: Research demonstrates a J-shaped relationship between bicarbonate and mortality in CKD stage 3b patients 1. Elevated bicarbonate levels (>32 mEq/L) are independently associated with increased all-cause mortality (HR 1.74,95% CI 1.52-2.00) 1.

• Increased heart failure risk: Each 1 mEq/L increase in bicarbonate above 24 mEq/L is associated with a 14% increased risk of heart failure events (HR 1.14,95% CI 1.03-1.26) 2.

Investigate the Cause

Immediately evaluate for:

1. Diuretic use - Loop or thiazide diuretics causing contraction alkalosis (most common cause)
2. Volume depletion - Check orthostatic vital signs, assess hydration status
3. Vomiting or nasogastric suction - Loss of gastric acid
4. Mineralocorticoid excess - Check blood pressure, serum potassium
5. Excessive alkali intake - Sodium bicarbonate, calcium carbonate antacids, or citrate-containing products

Key laboratory assessments:

• Serum potassium (hypokalemia often accompanies metabolic alkalosis) 3
• Urine chloride (helps differentiate causes: <20 mEq/L suggests volume depletion)
• Blood pressure (evaluate for hypertension suggesting mineralocorticoid excess)

Management Approach

Primary intervention depends on the underlying cause:

1. If diuretic-induced: Reduce diuretic dose or switch to potassium-sparing agents if clinically appropriate

2. If volume depleted: Administer isotonic saline (chloride-responsive alkalosis)

3. If mineralocorticoid excess: Consider mineralocorticoid receptor antagonist (though monitor potassium carefully in CKD 3b) 4

4. If excessive alkali intake: Discontinue or reduce alkali-containing medications

Monitoring Strategy

Do not attempt to "treat" the elevated bicarbonate with acid administration - this is not indicated and could be harmful. Instead:

• Monitor bicarbonate levels monthly until normalized
• Check serum potassium regularly, as hypokalemia (K+ <3.5 mEq/L) is associated with cardiovascular risk and mortality 3
• Reassess eGFR and albuminuria annually per CKD guidelines 5
• Monitor blood pressure closely, as alkalosis may indicate volume overload or mineralocorticoid activity

Important Caveats

Avoid overcorrection: The KDIGO 2024 guidelines emphasize that treatment for acid-base disorders should not result in bicarbonate exceeding the upper limit of normal, as you're experiencing here 4. Your goal is to normalize the bicarbonate to 22-29 mEq/L, not maintain it at 36 mEq/L.

Consider medication review: Many CKD patients are inappropriately given alkali therapy (sodium bicarbonate) when their bicarbonate is already normal or elevated 6. Verify this patient is not receiving unnecessary alkali supplementation.

Watch for fluid overload: Elevated bicarbonate with diuretic use may indicate inadequate diuresis or excessive alkali load, both requiring adjustment 4.